Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | POLA1 | P09884 | 6/20 | 0.50 |
| ▸ | SOD1 | P00441 | 1/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | GLI1 | P08151 | 2/20 | 0.38 |
| ▸ | ABHD16A | O95870 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL445153 | 1.00 | CYP3A4 (0.51) | CYP3A4MAPTALDH1A1ALOX15POLA1 | |
| Hydrochloric Acid SCHEMBL443967 | 0.85 | POLA1 (0.48) | CYP3A4MAPTALDH1A1ALOX15POLA1 | |
| SCHEMBL7767289 | 0.77 | POLA1 (0.81) | CYP3A4MAPTPOLA1SOD1NR1H2 | |
| SCHEMBL19770990 | 0.77 | POLA1 (0.81) | CYP3A4MAPTPOLA1SOD1NR1H2 | |
| SCHEMBL12292033 | 0.77 | POLA1 (0.81) | CYP3A4MAPTPOLA1SOD1NR1H2 | |
| SCHEMBL24177920 | 0.77 | POLA1 (0.81) | CYP3A4MAPTPOLA1SOD1NR1H2 | |
| SCHEMBL19786219 | 0.77 | POLA1 (0.81) | CYP3A4MAPTPOLA1SOD1NR1H2 | |
| SCHEMBL19786283 | 0.74 | POLA1 (0.47) | CYP3A4MAPTALDH1A1ALOX15POLA1 | |
| SCHEMBL19786281 | 0.74 | POLA1 (0.47) | CYP3A4MAPTALDH1A1ALOX15POLA1 | |
| SCHEMBL29409958 | 0.70 | CYP3A4 (0.69) | CYP3A4MAPTALDH1A1ALOX15POLA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140294763-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2014-10-02 | — | — | US | disclosed |
| EP-2368877-B1 | Peptidomimetic protease inhibitors and intermediates for their preparation As treatment for HCV infection | VERTEX PHARMA (US) | 2014-05-07 | — | — | EP | disclosed |
| US-20130344476-A1 | HEPATITIS C VIRUS VARIANTS | VERTEX PHARMACEUTICALS INCORPORATED | 2013-12-26 | — | — | US | disclosed |
| EP-1958956-B1 | Peptidomimetic protease inhibitors | VERTEX PHARMA (US) | 2013-12-11 | — | — | EP | disclosed |
| US-8529882-B2 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-10 | — | — | US | disclosed |
| US-8501450-B2 | Hepatitis C virus variants | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-06 | — | — | US | disclosed |
| EP-1951748-B1 | HEPATITIS C VIRUS VARIANTS | VERTEX PHARMA (US) | 2013-07-24 | — | — | EP | disclosed |
| US-20120282219-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-08 | — | — | US | disclosed |
| US-8252923-B2 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-28 | — | — | US | disclosed |
| EP-1678202-B1 | HCV NS3-NS4A PROTEASE RESISTANCE MUTANTS | VERTEX PHARMA (US) | 2012-06-13 | — | — | EP | disclosed |
| US-7494660-B2 | HCV NS3-NS4A protease resistance mutants | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-02-24 | — | — | US | disclosed |
| EP-1958956-A2 | Peptidomimetic protease inhibitors | Vertex Pharmaceuticals Incorporated (US) | 2008-08-20 | — | — | EP | disclosed |
| EP-1878720-A1 | Process for preparing chiral bicycloprolinates as intermediates for the preparation of peptidomimetic protease inhibitors | Vertex Pharmaceuticals Incorporated (US) | 2008-01-16 | — | — | EP | disclosed |
| EP-1876173-A1 | Chiral intermediates for the preparation of peptidomimetic protease inhibitors | Vertex Pharmaceuticals Incorporated (US) | 2008-01-09 | — | — | EP | disclosed |
| EP-1849797-A2 | Peptidomimetic protease inhibitors | Vertex Pharmaceuticals Incorporated (US) | 2007-10-31 | — | — | EP | disclosed |
| US-20070231262-A1 | Hepatitis C virus variants | VERTEX PHARMACEUTICALS, INCORPORATED | 2007-10-04 | — | — | US | disclosed |
| US-20050197299-A1 | Hepatitis C antiviral agents including telaprevir (VX 950); higher tolerance, reduced side effects; azaheterocyclic amido ketone derivatives | VERTEX PHARMACEUTICALS INCORPORATED | 2005-09-08 | — | — | US | disclosed |
| US-20050136400-A1 | NS3-NS4A protease resistance mutants | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-06-23 | — | — | US | disclosed |
| EP-1320540-A2 | PEPTIDOMIMETIC PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2003-06-25 | — | — | EP | disclosed |
| WO-2002018369-A2 | PEPTIDOMIMETIC PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197299-A1 | Hepatitis C antiviral agents including telaprevir (VX 950); higher tolerance, reduced side effects; azaheterocyclic amido ketone derivatives | CTRC, PEPD, CTSC | CYP3A4 133/4885MAPT 4585/4885ALDH1A1 1451/4885 |
| US-20140294763-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | CTSC, PREP, PEPD | CYP3A4 989/4885MAPT 4525/4885ALDH1A1 2218/4885 |
| US-20050136400-A1 | NS3-NS4A protease resistance mutants | ATG4A, CUL4A, DPP4 | CYP3A4 61/4885MAPT 3462/4885ALDH1A1 2526/4885 |
| US-20120282219-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | CTSC, PEPD, PREP | CYP3A4 1121/4885MAPT 4461/4885ALDH1A1 2639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.